---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-007107"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:20:16.749434+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion pivots to diabetes & obesity; icovamenib shows 1.5% HbA1c drop in insulin-deficient patients

## Summary
- Placebo-adjusted 1.5% mean HbA1c reduction in severe insulin-deficient T2D patients after 12 weeks of icovamenib, sustained 14 weeks off treatment.
- Placebo-adjusted 1.0% HbA1c reduction in patients uncontrolled on GLP-1 therapies, consistent with preclinical synergy with semaglutide.
- 100% of severely insulin-deficient patients on 100 mg icovamenib responded with durable HbA1c decline; no drug-related adverse events.
- Company plans to end oncology studies, seek partnerships, and focus on two late-stage trials: Phase 2/3 in insulin-deficient T2D and Phase 2b combo with GLP-1.
- Novel oral menin inhibitor designed to regenerate beta cells; FDA discussions expected to support late-stage development.

## SEC filing metadata
- accession: 0001193125-25-007107
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312525007107/0001193125-25-007107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312525007107/d830016d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-007107
- JSON: https://secwatch.observer/filing/0001193125-25-007107.json
- Plain text: https://secwatch.observer/filing/0001193125-25-007107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.